Gritstone bio
Neoantigen-vaccine pioneer (GRANITE, SLATE) that ran out of money and filed for bankruptcy in October 2024; a cautionary tale for the personalised-vaccine field.
Gritstone's GRANITE individualised neoantigen vaccine (adenoviral prime, samRNA boost) showed a molecular-response signal in a phase 2/3 colorectal cancer maintenance trial but not enough to fund completion. Chapter 11 filing 10 October 2024; assets sold at auction (Seattle Project Corp. and others) for about $21M in December 2024.
Pages like this
not linked directly; found by shared links- PersonYuquan Wei
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- InstitutionSidney Kimmel Comprehensive Cancer Center at Jefferson Health
- ProductDCVax-L
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines, Colorectal cancer.
- IdeaVaccinate against the resistance mutation before it takes over
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- CompanyNouscom
- TechnologySelf-amplifying and circular RNA therapeutics
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.